| 1 |
Slim MA，van Mourik N，Bakkerus L，et al. Towards personalized medicine：a scoping review of immunotherapy in sepsis ［J］. Crit Care，2024，28（1）：183.
|
| 2 |
Shankar-Hari M，Calandra T，Soares MP，et al. Reframing sepsis immunobiology for translation：towards informative subtyping and targeted immunomodulatory therapies ［J］. Lancet Respir Med，2024，12（4）：323-336.
|
| 3 |
Meizlish ML，Franklin RA，Zhou Ⅹ，et al. Tissue homeostasis and inflammation ［J］. Annu Rev Immunol，2021，39：557-581.
|
| 4 |
Medzhitov R，Schneider DS，Soares MP. Disease tolerance as a defense strategy ［J］. Science，2012，335（6071）：936-941.
|
| 5 |
Colaço HG，Barros A，Neves-Costa A，et al. Tetracycline antibiotics induce host-dependent disease tolerance to infection ［J］. Immunity，2021，54（1）：53-67.e7.
|
| 6 |
Ahuja SK，Manoharan MS，Lee GC，et al. Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection ［J］. Nat Commun，2023，14（1）：3286.
|
| 7 |
Buckley CD，Gilroy DW，Serhan CN，et al. The resolution of inflammation ［J］. Nat Rev Immunol，2013，13（1）：59-66.
|
| 8 |
裴飞，吴健锋. 评价脓毒症免疫抑制生物标志物的4个标准 ［J］. 中华检验医学杂志，2023，46（10）：992-996.
|
| 9 |
中国研究型医院学会休克与脓毒症专业委员会，中国人民解放军重症医学专业委员会，重症免疫研究协作组，等. 脓毒症免疫抑制诊治专家共识 ［J］. 中华危重病急救医学，2020，32（11）：1281-1289.
|
| 10 |
Wu JF，Ma J，Chen J，et al. Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis ［J］. Crit Care，2011，15（5）：R220.
|
| 11 |
Monneret G，Lepape A，Venet F. A dynamic view of mHLA-DR expression in management of severe septic patients ［J］. Crit Care，2011，15（5）：198.
|
| 12 |
Zhuang Y，Peng H，Chen Y，et al. Dynamic monitoring of monocyte HLA-DR expression for the diagnosis，prognosis，and prediction of sepsis ［J］. Front Biosci （Landmark Ed），2017，22（8）：1344-1354.
|
| 13 |
Yao RQ，Zhao PY，Li ZⅩ，et al. Single-cell transcriptome profiling of sepsis identifies HLA-DR（low）S100A（high） monocytes with immunosuppressive function ［J］. Mil Med Res，2023，10（1）：27.
|
| 14 |
Knoll R，Helbig ET，Dahm K，et al. The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation ［J］. Cell，2024，187（16）：4318-4335.e20.
|
| 15 |
Wu J，Pei F，Zhou L，et al. The efficacy and safety of thymosin α1 for sepsis （TESTS）：multicentre，double blinded，randomised，placebo controlled，phase 3 trial ［J］. BMJ，2025，388：e082583.
|
| 16 |
Pei F，Yao RQ，Ren C，et al. Expert consensus on the monitoring and treatment of sepsis-induced immunosuppression ［J］. Mil Med Res，2022，9（1）：74.
|
| 17 |
Sinha P，Kerchberger VE，Willmore A，et al. Identifying molecular phenotypes in sepsis：an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials ［J］.Lancet Respir Med，2023，11（11）：965-974.
|
| 18 |
Giamarellos-Bourboulis EJ，Aschenbrenner AC，Bauer M，et al.The pathophysiology of sepsis and precision-medicine-based immunotherapy ［J］. Nat Immunol，2024，25（1）：19-28.
|
| 19 |
杨翔，郭兰骐，谢剑锋，等. 转录组学在脓毒症诊疗中的临床研究进展 ［J/OL］. 中华重症医学电子杂志，2024，10（4）：384-388.
|
| 20 |
Misra AK，Levy MM，Ward NS. Biomarkers of immunosuppression ［J］.Crit Care Clin，2020，36（1）：167-176.
|
| 21 |
Yao RQ，Ren C，Zheng LY，et al. Advances in immune monitoring approaches for sepsis-induced immunosuppression ［J］. Front Immunol，2022，13：891024.
|
| 22 |
Meisel C，Schefold JC，Pschowski R，et al. Granulocytemacrophage colony-stimulating factor to reverse sepsis-associated immunosuppression：a double-blind，randomized，placebo-controlled multicenter trial ［J］. Am J Respir Crit Care Med，2009，180（7）：640-648.
|
| 23 |
Francois B，Jeannet R，Daix T，et al. Interleukin-7 restores lymphocytes in septic shock：the IRIS-7 randomized clinical trial ［J］. JCI Insight，2018，3（5）：e98960.
|
| 24 |
Reyes M，Filbin MR，Bhattacharyya RP，et al. An immune-cell signature of bacterial sepsis ［J］. Nat Med，2020，26（3）：333-340.
|
| 25 |
Yao RQ，Ren C，Zheng LY，et al. Advances in immune monitoring approaches for sepsis-induced immunosuppression ［J］. Front Immunol，2022，13：891024.
|
| 26 |
Yao RQ，Li ZⅩ，Wang LⅩ，et al. Single-cell transcriptome profiling of the immune space-time landscape reveals dendritic cell regulatory program in polymicrobial sepsis ［J］. Theranostics，2022，12（10）：4606-4628.
|
| 27 |
Wong HR. Intensive care medicine in 2050：precision medicine ［J］.Intensive Care Med，2017，43（10）：1507-1509.
|
| 28 |
Leventogiannis K，Kyriazopoulou E，Antonakos N，et al. Toward personalized immunotherapy in sepsis：the PROVIDE randomized clinical trial ［J］. Cell Rep Med，2022，3（11）：100817.
|
| 29 |
Kotsaki A，Pickkers P，Bauer M，et al. ImmunoSep （Personalised Immunotherapy in Sepsis） international double-blind，double-dummy，placebo-controlled randomised clinical trial：study protocol ［J］. BMJ Open，2022，12（12）：e067251.
|
| 30 |
Stanski NL，Wong HR. Prognostic and predictive enrichment in sepsis［J］. Nat Rev Nephrol，2020，16（1）：20-31.
|
| 31 |
Lara PN Jr，Moon J，Hesketh PJ，et al. SWOG S0709：Randomized phase ⅱ trial of Erlotinib versus Erlotinib plus Carboplatin/Paclitaxel in patients with advanced non-small cell lung cancer and impaired performance status as selected by a serum proteomics assay ［J］. J Thorac Oncol，2016，11（3）：420-425.
|
| 32 |
Rich P，Mitchell RB，Schaefer E，et al. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer ［J］. J Immunother Cancer，2021，9（10）：e002989.
|